The global cell lysis & disruption market size is expected to reach USD 7.95 billion by 2028 according to a new study by Polaris Market Research. The report “Cell Lysis & Disruption Market Share, Size, Trends, Industry Analysis Report, By Application (Protein Isolation, Downstream Processing, Cell Organelle Isolation, Nucleic Acid Isolation); By Technique; By Product; By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Some significant factors, such as the increasing investment by the various organizations and government to develop the biotechnological processes coupled with the expansion of the bio-pharmaceuticals industries, fuel the market growth. Besides, the rising application of this disruption systems methods in new gene expression protocols, as well as the growing innovations in instruments, homogenizers, and chemical methods, also contributes to the global market growth over the forecasting period.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/cell-lysis-disruption-market/request-for-sample
Based on technique, the reagent-based method segment is leading the industry and growing with the highest CAGR in the upcoming years. This method is not harming the biological activity of the ultimate products, perfectly suitable for laboratory samples, as well as this is mild. It is a preferable method across the globe. The physical methods segment is the second dominating segment since numerous industry vendors adopt it to extract intracellular contents.
Major participants such as BioVision, Inc., Cell Signaling Technology Inc., Becton Dickinson & Company (BD), Bio-Rad Laboratories, Danaher Corp., NZYTech Lda, Claremont BioSolutions, LLC, Merck KGaA, Covaris, Roche Molecular Systems, Inc., Geno Technology Inc., Microfluidics International Corp., Thermo Fisher Scientific, Miltenyi Biotec, Norgen Biotek Corp., Parr Instrument Company, PromoCell GmbH, Qsonica LLC, STEMCELL Technologies Inc., and are some of the key players operating in the global market.
There are various industry players and organizations that are launching new products into the global market for the treatment of various severe diseases. In March 2021, Novartis declared that The European Commission approved its Kesimpta for treating multiple sclerosis (RMS) among adults. Kesimpta is the first self-administered targeted, specifically dosed, and delivered B-cell therapy that exhibited the higher effectiveness with a parallel safety status with teriflunomide, the first-line treatment in MS2. Kesimpta works by binding to a different epitope that exists on the CD20 molecule, which induces effective B-cell lysis and disruption.
Polaris Market research has segmented the cell lysis & disruption market report on the basis of technique, product, application, end-use and region:
Cell Lysis & Disruption, Technique Outlook (Revenue, USD Billion, 2016 – 2028)
- Physical Disruption
- Mechanical Homogenization
- Ultrasonic Homogenization
- Pressure Homogenization
- Temperature Treatments
Cell Lysis & Disruption, Product Outlook (Revenue, USD Billion, 2016 – 2028)
- High Pressure Homogenizers
- French Press
- Bead Mill
- Reagents & Consumables
- Detergent Solutions
- Ionic detergent
- Nonionic detergent
- Zwitterionic detergent
- Kits & Reagents
Cell Lysis & Disruption, Application Outlook (Revenue, USD Billion, 2016 – 2028)
- Protein Isolation
- Downstream Processing
- Organelle Isolation
- Nucleic acid Isolation
Cell Lysis & Disruption, End-Use Outlook (Revenue, USD Billion, 2016 – 2028)
- Academic & Research Institutes
- Hospitals & Diagnostic Labs
- Pharmaceuticals & Biotechnology Companies
Cell Lysis & Disruption, Regional Outlook (Revenue, USD Billion, 2016 – 2028)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa